EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

5G Mobile Phone Technology and the Risk of Skin Cancer: A Risk Assessment by the SEAWave Consortium

Ljubica Zupunski iD, Theodoros Samaras iD, Olivier Gaide, Mariateresa Mancuso iD, Annette Bitsch, Myles Capstick, Christine Pich-Bavastro iD, Rosanna Pinto iD, Emanuelle Conil, Jens Kuhne iD, Serge Bories iD, Efthymios Karabetsos iD und 20 weitere

Bioelectromagnetics · 2026-12 · 47 (8)

DOI: 10.1002/bem.70075 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioelectromagnetics, online erschienen am 10.11.2026. Verfasst von Ljubica Zupunski und 31 weiteren Autor:innen. Beteiligte Einrichtung: International Agency for Research on Cancer (IARC), Environment and Lifestyle Epidemiology Branch, Lyon, France. Hauptthemen laut MEDLINE: Skin Neoplasms, Cell Phone, Radio Waves, Neoplasms, Radiation-Induced. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Union's Horizon Europe Framework Programme, SEAWave was also co-financed by the Swiss State Secretariat for Education, Research and Innovation (SERI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To meet the ever‐growing demands of wireless communication and enable new applications, the 5th generation (5G) New Radio (NR) cellular system was developed to offer better connectivity, to reduce latency, and enable higher data transfer rates. The use of the 5G frequency spectrum is divided into two frequency ranges, Frequency Range 1 (5G NR FR1) from 0.41 GHz to 7.125 GHz, operating in the same frequency range as the 2G–4G cellular systems and WLAN systems, and Frequency Range 2 (5G NR FR2) from 24.25 to 52.60 GHz using millimetre waves (mmWaves) to enable fast transfer of large amounts of data. Since 2019, FR1 has been rapidly deployed in Europe. Until today, in Europe, FR2 has very limited applications. The objective of SEAWave project was to conduct two risk assessments, one for FR1 and one for FR2. Risk assessment procedure included evaluation of evidence of an association between skin cancer and exposure to FR1 and FR2 radiofrequency electromagnetic field (RF‐EMF), with the skin being the most exposed organ during use. Both assessments are based on: a comprehensive review of the scientific literature available before the end of the project and the consolidated findings from research studies generated within the SEAWave project. Experiments conducted within SEAWave project included: (i) In vivo experiments on Carcinogenesis‐susceptible (Car‐S) mice and Patched heterozygous knockout mice (Ptch1 +/−) to investigate the effects of prolonged exposure to 5G FR2 RF‐EMF at 27.5 GHz on the development of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), two of the most common skin tumours. In addition, skin inflammation and nociceptive signalling were analysed in dorsal skin samples taken from mice after early stage whole‐body exposure in the first 21 days of postnatal life and after 100 days and 6 months of exposure; (ii) Clinical trial where participants' inner arms were exposed to 5G FR2 RF‐EMF at 27.5 GHz to study transcriptomic changes in skin samples induced by 5G FR2 RF‐EMF exposure, with particular attention to inflammatory processes; (iii) In vitro experiments using different primary human skin cell lines, that is, light‐pigmented primary epidermal juvenile and adult keratinocytes (NHEK‐f.c. and NHEK‐c.) and light‐pigmented primary epidermal adult melanocytes (NHEM) exposed to 5G FR2 RF‐EMF at 27.5 GHz to study several endpoints including genotoxicity, aneugenicity, telomere measurement, DNA methylation and transcriptomics. The overall evidence for an association between skin cancer and 5G FR1 has been classified as ‘inconclusive’ based on the evaluations of human evidence, evidence from animal studies and mechanistic studies classified as ‘inadequate’. 5G FR1 evaluations were mainly based on literature review. The overall evidence for an association between skin cancer and 5G FR2 has been classified as ‘inconclusive’ based on the evaluations of human evidence, and evidence from animal studies and mechanistic studies classified as ‘inadequate’. 5G FR2 evaluations were mainly based on findings from the SEAWave project. All classifications were unanimous except for the 5G FR2 mechanistic evidence which a minority considered ‘limited’; even with limited evidence the overall assessment for 5G FR2 would have remained ‘inconclusive’. An impact evaluation completes the risk assessment, as for inconclusive evidence no quantitative risk assessment could be carried out.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsCell PhoneRadio WavesNeoplasms, Radiation-InducedRisk AssessmentHumansAnimalsElectromagnetic Fields

Stichwörter der Autor:innen

electromagnetic fieldshazard identificationradio wavesrisk assessmentskin cancer

Autor:innen und Institutionen

  • International Agency for Research on Cancer (IARC), Environment and Lifestyle Epidemiology Branch, Lyon, France.
  • Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
  • Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), Rome, Italy.
  • Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
  • Foundation for Research on Information Technologies in Society (IT'IS Foundation), Zürich, Switzerland.

ORCID-Profile: Ljubica Zupunski, Theodoros Samaras, Mariateresa Mancuso, Christine Pich-Bavastro, Rosanna Pinto, Jens Kuhne, Serge Bories, Efthymios Karabetsos, Luc Martens, Niels Kuster, Christoph Böhmert, Shanshan Wang, Dimitrios Babas, Maria Christopoulou, Nirmala Prajapati, Günter Vermeeren, Michelle Djuari, Lucia Ardoino, Serafeim Iakovidis, Athanasios Manassas, Christina Ziemann, Joachim Schüz

Förderung

  • European Union's Horizon Europe Framework Programme
  • SEAWave was also co-financed by the Swiss State Secretariat for Education, Research and Innovation (SERI)

Zitieren

APA

Zupunski, L., Samaras, T., Gaide, O., Mancuso, M., Bitsch, A., Capstick, M., Pich-Bavastro, C., Pinto, R., Conil, E., Kuhne, J., Bories, S., Karabetsos, E., Martens, L., Gajsek, P., Kuster, N., Böhmert, C., Kühn, S., Wang, S., Babas, D., …, & Schüz, J. (2026). 5G Mobile Phone Technology and the Risk of Skin Cancer: A Risk Assessment by the SEAWave Consortium. Bioelectromagnetics, 47(8). https://doi.org/10.1002/bem.70075

Vancouver

Zupunski L, Samaras T, Gaide O, Mancuso M, Bitsch A, Capstick M, et al. 5G Mobile Phone Technology and the Risk of Skin Cancer: A Risk Assessment by the SEAWave Consortium. Bioelectromagnetics. 2026;47(8). doi:10.1002/bem.70075

BibTeX
@article{Zupunski2026,
  author = {Zupunski, Ljubica and Samaras, Theodoros and Gaide, Olivier and Mancuso, Mariateresa and Bitsch, Annette and Capstick, Myles and Pich-Bavastro, Christine and Pinto, Rosanna and Conil, Emanuelle and Kuhne, Jens and Bories, Serge and Karabetsos, Efthymios and Martens, Luc and Gajsek, Peter and Kuster, Niels and Böhmert, Christoph and Kühn, Sven and Wang, Shanshan and Babas, Dimitrios and Christopoulou, Maria and Prajapati, Nirmala and Vermeeren, Günter and Valic, Blaz and Djuari, Michelle and Apostolidis, Christos and Su, Zhouxing and Ardoino, Lucia and Iakovidis, Serafeim and Manassas, Athanasios and Ziemann, Christina and Dasenbrock, Clemens and Schüz, Joachim},
  title = {5G Mobile Phone Technology and the Risk of Skin Cancer: A Risk Assessment by the SEAWave Consortium},
  journal = {Bioelectromagnetics},
  year = {2026},
  volume = {47},
  number = {8},
  doi = {10.1002/bem.70075}
}
Kostenlos starten →